Skip to Content
Merck
  • Excessive activation of the alternative complement pathway in autosomal dominant polycystic kidney disease.

Excessive activation of the alternative complement pathway in autosomal dominant polycystic kidney disease.

Journal of internal medicine (2014-02-06)
Z Su, X Wang, X Gao, Y Liu, C Pan, H Hu, R P Beyer, M Shi, J Zhou, J Zhang, A L Serra, R P Wüthrich, C Mei
ABSTRACT

The complement system is involved in many immune complex-mediated kidney diseases, yet its role in the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD) has not been examined in detail. Screening of the glycoproteome of urine samples from ADPKD patients revealed that levels of complement factor B (CFB), serpin peptidase inhibitor, complement component 1 inhibitor (SERPING1) and complement component 9 (C9) increased, whereas complement component 1, r subcomponent-like (C1RL), CD55 and CD59 levels decreased with disease progression. Immunostaining and Western blot analysis confirmed the enhanced expression of CFB and C9 in cystic kidneys from ADPKD patients. Immunostaining also showed that the expressions of CFB and C9 in renal biopsy tissues from patients with other types of chronic kidney disease were lower than in tissues from ADPKD patients. The effect of the complement inhibitor rosmarinic acid (RMA) was evaluated in Pkd1(-/-) mice and Han:SPRD Cy/+ rats. Compared with vehicle-treated Pkd1(-/-) animals, RMA-treated mice had significantly lower serum creatinine (-50%) and blood urea nitrogen (-78%) levels, two kidneys/body weight ratio (-60%) and renal cystic index (-60%). Similar results were found in Cy/+ rats. Lower numbers of Ki67-positive nuclei and inflammatory cells and reduced fibrosis were observed in both animal models upon treatment with RMA. These results suggest that excessive activation of the alternative complement pathway is associated with ADPKD progression, probably mediated by cyst-lining epithelial cell proliferation, tubulointerstitial inflammatory cell infiltration and fibrosis. Targeting the complement system might represent a new therapeutic strategy for ADPKD.

MATERIALS
Product Number
Brand
Product Description

Rosmarinic acid, primary reference standard
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Rosmarinic acid, ≥98% (HPLC), from Rosemarinus officinalis L.
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Rosmarinic acid, 96%
SKU
Pack Size
Availability
Price
Quantity
Rosmarinic acid, European Pharmacopoeia (EP) Reference Standard
SKU
Pack Size
Availability
Price
Quantity
Hydrochlorothiazide for peak identification, European Pharmacopoeia (EP) Reference Standard
SKU
Pack Size
Availability
Price
Quantity
Hydrochlorothiazide, European Pharmacopoeia (EP) Reference Standard
SKU
Pack Size
Availability
Price
Quantity
Supelco
Hydrochlorothiazide, Pharmaceutical Secondary Standard; Certified Reference Material
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Hydrochlorothiazide, crystalline
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Hydrochlorothiazide, meets USP testing specifications
SKU
Pack Size
Availability
Price
Quantity
USP
Hydrochlorothiazide, United States Pharmacopeia (USP) Reference Standard
SKU
Pack Size
Availability
Price
Quantity